Clinical Trial Update: Ph1 Volasertib Plus Romidepsin in R/R PTCL and CTCL [Phase 1]

View source ↗

Summary

This update reports the withdrawal of a Phase 1 study evaluating volasertib plus romidepsin for relapsed/refractory peripheral T-cell lymphoma and cutaneous T-c…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cutaneous T-cell Lymphoma
• Peripheral T-cell Lymphoma

Drugs mentioned

• Istodax (romidepsin)
• Volasertib (Volasertib)

Snippet

Sponsor: Anne Beaven, MD | Conditions: PTCL, CTCL | Phase 1 | Status: WITHDRAWN